English / Français

FDA approval of a paediatric formulation of dolutegravir brings hope to infants and young children living with HIV around the world

MPP thanks Unitaid for new 5-year grant and acknowledges the key role partners – including originators and generic manufacturers – have played in making affordable quality medicines accessible

Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies

Algeria gains inclusion to ViiV Healthcare and MPP adult licence enabling greater access to dolutegravir-based HIV treatments

MPP's Panel Discussion at the World Health Summit 2020

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).

Featured

COVID-19 Open Pledge

12 November 2020

Kenya

26 October 2020

MPP in Numbers

patent holders with MPP signed agreements

generic manufacturers and product developers have sublicences from MPP

countries have benefitted from access to MPP-licensed products

ongoing pharmaceutical development projects

0Bn

Billion dollars saved by the international community, from January 2012 to June 2020

0Bn

Billion doses of treatment supplied from January 2012 to June 2020

0Mn

Million patient-years of treatment through MPP’s generic partners, from January 2012 to June 2020

For Everyone Everywhere

Discover where we helped and what we have achieved

Additional Tools

Business Model

Prioritising Medicines for Licensing

Licences

MedsPaL

Key Publications

Annual Reports

06 October 2020

MPP Publications

MPP framework for prioritising target medicines for in-licensing under its newly expanded mandate

09 May 2019

MPP Publications